AngioDynamics is benefiting from strong NanoKnife growth and broad Med Tech momentum, though tariff and inflation pressures persist. NanoKnife revenues rose 21% year over year to $7.6 million in the fiscal third quarter of 2026, driven by higher probe and capital sales amid favorable reimbursement trends following the January 1, 2026 CPT Category I code implementation. The Auryon platform grew 17.9% to $16.3 million, marking its 19th consecutive quarter of double-digit growth, while the Mechanical Thrombectomy business, combining AngioVac and AlphaVac, increased 17.9% to $11.5 million, with AlphaVac surging 47.4%. Overall third-quarter results beat expectations on both revenue and adjusted loss per share, but gross margin contracted 110 basis points to 52.9% due to tariffs, inflation, and manufacturing transition costs, with management reiterating $4 million to $6 million in expected tariff-related costs for fiscal 2026. The Zacks Consensus Estimate for fiscal 2026 loss per share has remained stable at 19 cents over the past 30 days.
Globus Medical
Intuitive Surgical IncAngioDynamics IncNanoKnife revenues rose 21% YoY, Auryon grew 17.9%, and AlphaVac surged 47.4%, all indicating strong product demand.
West Pharmaceutical Services Inc